ATHE — Alterity Therapeutics Limited

Summary of Alterity Therapeutics Q2 2021 Earnings Call

1. Key Financial Results and Metrics

• Operating Loss: $8.6 million for the half-year period.
• Net Operating Cash Outflow: $7.3 million.
• Cash Position: $35 million as of December 31, buoyed by a $35 million capital raise from institutional investors.
• Revenue: No revenue reported, as the company remains in a development stage.

2. Strategic Updates and Business Highlights

• Leadership Change: Dr. David Stamler appointed CEO, succeeding Founder Geoffrey Kempler, reflecting progress in the development of lead compound ATH434.
• ATH434 Development: Completed Phase I trials and preparing for Phase II studies targeting Multiple System Atrophy (MSA), a rare Parkinsonian disorder.
• Natural History Study: Launched bioMUSE study in collaboration with Vanderbilt University to inform Phase II trial design.
• New Patent: Received allowance for a patent covering over 150 novel compounds related to iron redistribution, expanding the therapeutic portfolio.
• PBT2 Development: Secured a license for using PBT2 in combating antimicrobial resistance, addressing a significant public health issue.
• Funding Support: Awarded a grant of nearly $500,000 from the Michael J. Fox Foundation to evaluate ATH434 in primate models.

3. Forward Guidance and Outlook

• Clinical Trials: Expect to commence Phase II trial for ATH434 in the second half of the year, pending regulatory feedback from European health authorities.
• Research Publications: Anticipate publishing new research findings on ATH434's mechanism and efficacy later in the year.
• Market Potential: Significant interest in PBT2 for addressing antimicrobial resistance, with plans to seek non-dilutive funding for development.

4. Bad News, Challenges, or Points of Concern

• No Revenue Generation: As a development-stage company, Alterity has yet to generate revenue, relying on grants and capital raises.
• Regulatory Challenges: Lack of regulatory precedence for MSA trials poses challenges in trial design and endpoints.
• PBT2 Clinical Hold: Previous partial clinical hold by the FDA for Alzheimer’s may impact future trials and requires careful navigation in development plans.

5. Notable Q&A Insights

• ATH434 Phase II Preparation: Progressing well with ongoing manufacturing and preclinical work; guidance from European regulators expected soon.
• Interest from Big Pharma: Ongoing discussions with large pharmaceutical companies about potential partnerships.
• Market Value of PBT2: While the market potential for PBT2 in antimicrobial resistance is significant, specific estimates are not yet available.
• Mitochondrial Studies: Plans to investigate the impact of ATH434 on mitochondrial function are underway.
• Future Research: Commitment to exploring new compounds identified in the recently issued patent and optimizing them for development.

Overall, Alterity Therapeutics is making significant strides in its drug development programs, particularly with ATH434 and PBT2, while navigating the challenges typical of a development-stage biopharmaceutical company.